<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02809183</url>
  </required_header>
  <id_info>
    <org_study_id>TRCA-101</org_study_id>
    <secondary_id>2015-004327-31</secondary_id>
    <nct_id>NCT02809183</nct_id>
  </id_info>
  <brief_title>Evaluation of TRC101 in Subjects With Chronic Kidney Disease and Metabolic Acidosis</brief_title>
  <official_title>A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of TRC101 in Subjects With Chronic Kidney Disease and Low Serum Bicarbonate Levels</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tricida, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tricida, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was a double-blind, placebo-controlled, parallel-design, 6-arm, fixed dose study. The
      study enrolled 135 adult male and female subjects with Stage 3 or 4 chronic kidney disease
      and low serum bicarbonate levels. The study was conducted in two parts. In Part 1 study drug
      dosing (TRC101 or placebo) continued for 14 days twice daily (BID). In Part 2 study drug
      dosing (TRC101 or placebo) continued for 14 days once daily (QD).

      The maximum study duration per subject was anticipated to be up to 42 days.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2016</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With Treatment Emergent Adverse Events (TEAEs) and Number of Subjects Who Discontinued Study Drug Due to a TEAE</measure>
    <time_frame>Through treatment period completion (Day 15)</time_frame>
    <description>The number and percentage of subjects who reported treatment-emergent adverse events (TEAEs) summarized by system organ class and preferred term (see Reported Adverse Events) as well as by severity, causality, seriousness, and action taken with regard to study drug. All analyses were descriptive.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline to the End of Treatment (Day 15) in Serum Bicarbonate Within Each Individual TRC101 Dose Group</measure>
    <time_frame>Baseline and Day 15</time_frame>
    <description>Serum bicarbonate at Day 15 minus serum bicarbonate at Baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of Change From Baseline in Serum Bicarbonate at Day 15 Between Each TRC101 Dose Group Versus Placebo</measure>
    <time_frame>Baseline and Day 15</time_frame>
    <description>Serum bicarbonate at Day 15 minus serum bicarbonate at Baseline for each TRC101 dose group versus that for Placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Serum Bicarbonate at Day 15 Within the Combined TRC101 Treatment Group</measure>
    <time_frame>Baseline and Day 15</time_frame>
    <description>Serum bicarbonate at Day 15 minus serum bicarbonate at Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Change From Baseline in Serum Bicarbonate at Day 15 Between the Combined TRC101 Treatment Group Versus Placebo</measure>
    <time_frame>Baseline and Day 15</time_frame>
    <description>Serum bicarbonate at Day 15 minus serum bicarbonate at Baseline for the Combined TRC101 Treatment Group versus that for Placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the Proportion of Subjects Whose Serum Bicarbonate Values Increased From Baseline to Day 15 by Greater Than or Equal to 2, 3, or 4 mEq/L Between Each TRC101 Dose Group Versus Placebo</measure>
    <time_frame>Baseline and Day 15</time_frame>
    <description>Comparison of the proportion of subjects whose serum bicarbonate values increased from Baseline to Day 15 by greater than or equal to 2, 3, or 4 mEq/L between each TRC101 BID Dose Group versus Placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Serum Bicarbonate at Day 15 Within the TRC101 6g QD Dose Group</measure>
    <time_frame>Baseline and Day 15</time_frame>
    <description>Serum bicarbonate at Day 15 minus serum bicarbonate at Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Serum Bicarbonate at Day 15 Comparison Between the TRC101 6g QD Dose Group Versus Placebo</measure>
    <time_frame>Baseline and Day 15</time_frame>
    <description>Serum bicarbonate at Day 15 minus serum bicarbonate at Baseline for the TRC101 6g dose group versus that for Placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Serum Bicarbonate at Day 15 Comparison Between the TRC101 6g QD Dose Group Versus the TRC101 3g BID Dose Group</measure>
    <time_frame>Baseline and Day 15</time_frame>
    <description>Serum bicarbonate at Day 15 minus serum bicarbonate at Baseline for the TRC101 6g QD dose group versus that for the TRC101 3g BID dose group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the Proportion of Subjects in the TRC101 6g QD Dose Group Whose Serum Bicarbonate Values Increased From Baseline to Day 15 by Greater Than or Equal to 2, 3, or 4 mEq/L Versus Placebo</measure>
    <time_frame>Baseline and Day 15</time_frame>
    <description>Comparison of the proportion of subjects whose serum bicarbonate values increased from Baseline to Day 15 by greater than or equal to 2, 3, or 4 mEq/L between the 6g TRC101 QD Dose Group versus Placebo</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">135</enrollment>
  <condition>Acidosis</condition>
  <arm_group>
    <arm_group_label>Placebo-BID</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administered twice daily (BID) for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TRC101 (1.5g BID)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered twice daily (BID) for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TRC101 (3g BID)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered twice daily (BID) for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TRC101 (4.5g BID)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered twice daily (BID) for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TRC101 (6g QD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered once daily (QD) for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo-QD</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administered once daily (QD) for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral suspension</description>
    <arm_group_label>Placebo-BID</arm_group_label>
    <arm_group_label>Placebo-QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TRC101</intervention_name>
    <description>oral suspension</description>
    <arm_group_label>TRC101 (1.5g BID)</arm_group_label>
    <arm_group_label>TRC101 (3g BID)</arm_group_label>
    <arm_group_label>TRC101 (4.5g BID)</arm_group_label>
    <arm_group_label>TRC101 (6g QD)</arm_group_label>
    <other_name>Veverimer</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Estimated glomerular filtration rate (eGFR) of 20 to &lt;60 mL/min/1.73m2

          -  Serum bicarbonate level of 12 to 20 mEq/L

        Exclusion Criteria:

          -  Any level of low serum bicarbonate that, in the opinion of the Investigator, requires
             emergency intervention.

          -  Severe comorbid conditions other than chronic kidney disease.

          -  Chronic obstructive pulmonary disease.

          -  Anticipated changes in doses of any of the following drugs or drug classes: diuretics,
             non-ophthalmic carbonic anhydrase inhibitors, oral diabetes drugs, antihypertensive
             drugs, antacids, H2-blockers, or proton pump inhibitors.

          -  Excluded drugs or drug classes: insulin, non-daily or &quot;as needed&quot; diuretics, herbal
             products, dietary supplements, multivitamins, naturopathic remedies, sodium
             bicarbonate, potassium citrate, sodium citrate or other alkali therapy, non-steroidal
             anti-inflammatory drugs (NSAIDs), fiber supplements, laxatives, calcium and magnesium
             supplements, or electrolyte binders and other binder drugs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuri Stasiv, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Tricida, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigative Site 1</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site 3</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site 4</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site 5</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site 6</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Georgia</country>
  </location_countries>
  <results_reference>
    <citation>Bushinsky DA, Hostetter T, Klaerner G, Stasiv Y, Lockey C, McNulty S, Lee A, Parsell D, Mathur V, Li E, Buysse J, Alpern R. Randomized, Controlled Trial of TRC101 to Increase Serum Bicarbonate in Patients with CKD. Clin J Am Soc Nephrol. 2018 Jan 6;13(1):26-35. doi: 10.2215/CJN.07300717. Epub 2017 Nov 4. Erratum in: Clin J Am Soc Nephrol. 2019 Feb 7;14(2):277.</citation>
    <PMID>29102959</PMID>
  </results_reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>June 14, 2016</study_first_submitted>
  <study_first_submitted_qc>June 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2016</study_first_posted>
  <results_first_submitted>November 21, 2019</results_first_submitted>
  <results_first_submitted_qc>January 2, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 14, 2020</results_first_posted>
  <disposition_first_submitted>November 30, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>November 30, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">December 6, 2017</disposition_first_posted>
  <last_update_submitted>January 2, 2020</last_update_submitted>
  <last_update_submitted_qc>January 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metabolic acidosis</keyword>
  <keyword>serum bicarbonate</keyword>
  <keyword>kidney disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Acidosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo BID</title>
          <description>Placebo administered twice daily (BID) for 14 days</description>
        </group>
        <group group_id="P2">
          <title>1.5g TRC101 BID</title>
          <description>1.5g TRC101 administered twice daily (BID) for 14 days</description>
        </group>
        <group group_id="P3">
          <title>3g TRC101 BID</title>
          <description>3g TRC101 administered twice daily (BID) for 14 days</description>
        </group>
        <group group_id="P4">
          <title>4.5g TRC101 BID</title>
          <description>4.5g TRC101 administered twice daily (BID) for 14 days</description>
        </group>
        <group group_id="P5">
          <title>Placebo QD</title>
          <description>Placebo administered once daily (QD) for 14 days</description>
        </group>
        <group group_id="P6">
          <title>6g TRC101 QD</title>
          <description>6g TRC101 administered once daily (QD) for 14 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="26"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="26"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent-to-treat (ITT) population</population>
      <group_list>
        <group group_id="B1">
          <title>Pooled Placebo</title>
          <description>Pooled placebo treatment groups (Placebo administered twice daily [BID] for 14 days + Placebo administered once daily [QD] for 14 days)</description>
        </group>
        <group group_id="B2">
          <title>1.5g TRC101 BID</title>
          <description>1.5g TRC101 administered twice daily (BID) for 14 days</description>
        </group>
        <group group_id="B3">
          <title>3g TRC101 BID</title>
          <description>3g TRC101 administered twice daily (BID) for 14 days</description>
        </group>
        <group group_id="B4">
          <title>4.5g TRC101 BID</title>
          <description>4.5g TRC101 administered twice daily (BID) for 14 days</description>
        </group>
        <group group_id="B5">
          <title>6g TRC101 QD</title>
          <description>6g TRC101 administered once daily (QD) for 14 days</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="25"/>
            <count group_id="B4" value="26"/>
            <count group_id="B5" value="28"/>
            <count group_id="B6" value="135"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" spread="12"/>
                    <measurement group_id="B2" value="58" spread="14"/>
                    <measurement group_id="B3" value="60" spread="13"/>
                    <measurement group_id="B4" value="61" spread="13"/>
                    <measurement group_id="B5" value="63" spread="11"/>
                    <measurement group_id="B6" value="60.3" spread="12.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="16"/>
                    <measurement group_id="B6" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="17"/>
                    <measurement group_id="B6" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hypertension</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="26"/>
                    <measurement group_id="B6" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Heart Failure</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum Bicarbonate</title>
          <units>mEq/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17.6" spread="1.4"/>
                    <measurement group_id="B2" value="18.0" spread="1.0"/>
                    <measurement group_id="B3" value="17.8" spread="1.2"/>
                    <measurement group_id="B4" value="17.5" spread="1.3"/>
                    <measurement group_id="B5" value="17.7" spread="1.0"/>
                    <measurement group_id="B6" value="17.72" spread="1.197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>eGFR</title>
          <units>mL/min/1.73m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34" spread="14"/>
                    <measurement group_id="B2" value="35" spread="13"/>
                    <measurement group_id="B3" value="40" spread="13"/>
                    <measurement group_id="B4" value="35" spread="13"/>
                    <measurement group_id="B5" value="31" spread="10"/>
                    <measurement group_id="B6" value="35.70" spread="12.419"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Treatment Emergent Adverse Events (TEAEs) and Number of Subjects Who Discontinued Study Drug Due to a TEAE</title>
        <description>The number and percentage of subjects who reported treatment-emergent adverse events (TEAEs) summarized by system organ class and preferred term (see Reported Adverse Events) as well as by severity, causality, seriousness, and action taken with regard to study drug. All analyses were descriptive.</description>
        <time_frame>Through treatment period completion (Day 15)</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo</title>
            <description>Pooled placebo treatment groups (Placebo administered twice daily [BID] for 14 days + Placebo administered once daily [QD] for 14 days)</description>
          </group>
          <group group_id="O2">
            <title>1.5g TRC101 BID</title>
            <description>1.5g TRC101 administered twice daily (BID) for 14 days</description>
          </group>
          <group group_id="O3">
            <title>3g TRC101 BID</title>
            <description>3g TRC101 administered twice daily (BID) for 14 days</description>
          </group>
          <group group_id="O4">
            <title>4.5g TRC101 BID</title>
            <description>4.5g TRC101 administered twice daily (BID) for 14 days</description>
          </group>
          <group group_id="O5">
            <title>6g TRC101 QD</title>
            <description>6g TRC101 administered once daily (QD) for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Treatment Emergent Adverse Events (TEAEs) and Number of Subjects Who Discontinued Study Drug Due to a TEAE</title>
          <description>The number and percentage of subjects who reported treatment-emergent adverse events (TEAEs) summarized by system organ class and preferred term (see Reported Adverse Events) as well as by severity, causality, seriousness, and action taken with regard to study drug. All analyses were descriptive.</description>
          <population>Safety Analysis Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects Reporting any TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 1 Mild TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 1 Moderate TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 1 Severe TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 1 Serious TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Drug Discontinuation Due to TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to the End of Treatment (Day 15) in Serum Bicarbonate Within Each Individual TRC101 Dose Group</title>
        <description>Serum bicarbonate at Day 15 minus serum bicarbonate at Baseline</description>
        <time_frame>Baseline and Day 15</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo</title>
            <description>Pooled placebo treatment groups (Placebo administered twice daily [BID] for 14 days + Placebo administered once daily [QD] for 14 days)</description>
          </group>
          <group group_id="O2">
            <title>1.5g TRC101 BID</title>
            <description>1.5g TRC101 administered twice daily (BID) for 14 days</description>
          </group>
          <group group_id="O3">
            <title>3g TRC101 BID</title>
            <description>3g TRC101 administered twice daily (BID) for 14 days</description>
          </group>
          <group group_id="O4">
            <title>4.5g TRC101 BID</title>
            <description>4.5g TRC101 administered twice daily (BID) for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to the End of Treatment (Day 15) in Serum Bicarbonate Within Each Individual TRC101 Dose Group</title>
          <description>Serum bicarbonate at Day 15 minus serum bicarbonate at Baseline</description>
          <population>Full Analysis Set</population>
          <units>mEq/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="0.4"/>
                    <measurement group_id="O2" value="3.2" spread="0.4"/>
                    <measurement group_id="O3" value="3.0" spread="0.4"/>
                    <measurement group_id="O4" value="3.7" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Single-group test</non_inferiority_desc>
            <p_value>0.5547</p_value>
            <p_value_desc>The null hypothesis is that the mean change from baseline within the Pooled Placebo treatment group = 0 mEq/L.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Group LS mean</param_type>
            <param_value>-0.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.9</ci_lower_limit>
            <ci_upper_limit>0.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that the mean change from baseline within the 1.5g TRC101 BID treatment group = 0 mEq/L.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Single-group test</non_inferiority_desc>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>The null hypothesis is that the mean change from baseline within the 1.5g TRC101 BID group = 0 mEq/L</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Group LS mean</param_type>
            <param_value>3.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.4</ci_lower_limit>
            <ci_upper_limit>4.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Single-group test</non_inferiority_desc>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>The null hypothesis is the 3g TRC101 BID treatment group mean change from baseline = 0 mEq/L.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Group LS mean</param_type>
            <param_value>3.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.2</ci_lower_limit>
            <ci_upper_limit>3.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Single-group test</non_inferiority_desc>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>The null hypothesis is the 4.5g TRC101 BID treatment group mean change from baseline = 0 mEq/L</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Group LS mean</param_type>
            <param_value>3.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.9</ci_lower_limit>
            <ci_upper_limit>4.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Change From Baseline in Serum Bicarbonate at Day 15 Between Each TRC101 Dose Group Versus Placebo</title>
        <description>Serum bicarbonate at Day 15 minus serum bicarbonate at Baseline for each TRC101 dose group versus that for Placebo</description>
        <time_frame>Baseline and Day 15</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo</title>
            <description>Pooled placebo treatment groups (Placebo administered twice daily [BID] for 14 days + Placebo administered once daily [QD] for 14 days)</description>
          </group>
          <group group_id="O2">
            <title>1.5g TRC101 BID</title>
            <description>1.5g TRC101 administered twice daily (BID) for 14 days</description>
          </group>
          <group group_id="O3">
            <title>3g TRC101 BID</title>
            <description>3g TRC101 administered twice daily (BID) for 14 days</description>
          </group>
          <group group_id="O4">
            <title>4.5g TRC101 BID</title>
            <description>4.5g TRC101 administered twice daily (BID) for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Change From Baseline in Serum Bicarbonate at Day 15 Between Each TRC101 Dose Group Versus Placebo</title>
          <description>Serum bicarbonate at Day 15 minus serum bicarbonate at Baseline for each TRC101 dose group versus that for Placebo</description>
          <population>Full Analysis Set</population>
          <units>mEq/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="0.4"/>
                    <measurement group_id="O2" value="3.2" spread="0.4"/>
                    <measurement group_id="O3" value="3.0" spread="0.4"/>
                    <measurement group_id="O4" value="3.7" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Two-group test</non_inferiority_desc>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>The null hypothesis is the difference between treatment groups (1.5g TRC101 BID - Pooled Placebo) in the mean change from baseline = 0 mEq/L.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Difference between group LS means</param_type>
            <param_value>3.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.5</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.3</ci_lower_limit>
            <ci_upper_limit>4.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Two-group test</non_inferiority_desc>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>The null hypothesis is the difference between treatment groups (3g TRC101 BID - Pooled Placebo) in the mean change from baseline = 0 mEq/L.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Difference between group LS means</param_type>
            <param_value>3.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.5</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.2</ci_lower_limit>
            <ci_upper_limit>4.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Two-group test</non_inferiority_desc>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>The null hypothesis is the difference between the treatment groups (4.5g TRC101 BID - Pooled Placebo) in the mean change from baseline = 0 mEq/L.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Difference between group LS means</param_type>
            <param_value>3.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.5</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.9</ci_lower_limit>
            <ci_upper_limit>5.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Serum Bicarbonate at Day 15 Within the Combined TRC101 Treatment Group</title>
        <description>Serum bicarbonate at Day 15 minus serum bicarbonate at Baseline</description>
        <time_frame>Baseline and Day 15</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Combined TRC101</title>
            <description>Combined groups treated with TRC101 for 14 days (TRC101 BID: 1.5g, 3g and 4.5g; TRC101 QD: 6g)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Serum Bicarbonate at Day 15 Within the Combined TRC101 Treatment Group</title>
          <description>Serum bicarbonate at Day 15 minus serum bicarbonate at Baseline</description>
          <population>Full Analysis Set</population>
          <units>mEq/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Single-group test</non_inferiority_desc>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>The null hypothesis is that the mean change from baseline within the Combined TRC101 treatment group = 0 mEq/L.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Group LS mean</param_type>
            <param_value>3.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.2</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.0</ci_lower_limit>
            <ci_upper_limit>3.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Change From Baseline in Serum Bicarbonate at Day 15 Between the Combined TRC101 Treatment Group Versus Placebo</title>
        <description>Serum bicarbonate at Day 15 minus serum bicarbonate at Baseline for the Combined TRC101 Treatment Group versus that for Placebo</description>
        <time_frame>Baseline and Day 15</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo</title>
            <description>Pooled placebo treatment groups (Placebo administered twice daily [BID] for 14 days + Placebo administered once daily [QD] for 14 days)</description>
          </group>
          <group group_id="O2">
            <title>Combined TRC101</title>
            <description>Combined groups treated with TRC101 for 14 Days (TRC101 BID: 1.5g, 3g and 4.5g; TRC101 QD: 6g)</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Change From Baseline in Serum Bicarbonate at Day 15 Between the Combined TRC101 Treatment Group Versus Placebo</title>
          <description>Serum bicarbonate at Day 15 minus serum bicarbonate at Baseline for the Combined TRC101 Treatment Group versus that for Placebo</description>
          <population>Full Analysis Set</population>
          <units>mEq/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="0.4"/>
                    <measurement group_id="O2" value="3.3" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Two-group test</non_inferiority_desc>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>The null hypothesis is that the difference between treatment groups (Combined TRC101 - Pooled Placebo) in the mean change from baseline = 0 mEq/L.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Difference between group LS means</param_type>
            <param_value>3.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.8</ci_lower_limit>
            <ci_upper_limit>4.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of the Proportion of Subjects Whose Serum Bicarbonate Values Increased From Baseline to Day 15 by Greater Than or Equal to 2, 3, or 4 mEq/L Between Each TRC101 Dose Group Versus Placebo</title>
        <description>Comparison of the proportion of subjects whose serum bicarbonate values increased from Baseline to Day 15 by greater than or equal to 2, 3, or 4 mEq/L between each TRC101 BID Dose Group versus Placebo</description>
        <time_frame>Baseline and Day 15</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo</title>
            <description>Pooled placebo treatment groups (Placebo administered twice daily [BID] for 14 days + Placebo administered once daily [QD] for 14 days)</description>
          </group>
          <group group_id="O2">
            <title>1.5g TRC101 BID</title>
            <description>1.5g TRC101 administered twice daily (BID) for 14 days</description>
          </group>
          <group group_id="O3">
            <title>3g TRC101 BID</title>
            <description>3g TRC101 administered twice daily (BID) for 14 days</description>
          </group>
          <group group_id="O4">
            <title>4.5g TRC101 BID</title>
            <description>4.5g TRC101 administered twice daily (BID) for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of the Proportion of Subjects Whose Serum Bicarbonate Values Increased From Baseline to Day 15 by Greater Than or Equal to 2, 3, or 4 mEq/L Between Each TRC101 Dose Group Versus Placebo</title>
          <description>Comparison of the proportion of subjects whose serum bicarbonate values increased from Baseline to Day 15 by greater than or equal to 2, 3, or 4 mEq/L between each TRC101 BID Dose Group versus Placebo</description>
          <population>Full Analysis Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>=&gt; 2 mEq/L Baseline Serum Bicarbonate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>=&gt; 3 mEq/L Baseline Serum Bicarbonate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>=&gt; 4 mEq/L Baseline Serum Bicarbonate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Two-group test</non_inferiority_desc>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>The null hypothesis is that the difference between treatment groups (1.5g TRC101 BID - Pooled Placebo) in proportion of subjects whose serum bicarbonate increased from baseline to Day 15 by =&gt; 2 mEq/L = 0.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Two-group test</non_inferiority_desc>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>The null hypothesis is that the difference between treatment groups (1.5g TRC101 BID - Pooled Placebo) in proportion of subjects whose serum bicarbonate increased from baseline to Day 15 by =&gt; 3 mEq/L = 0.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Two-group test</non_inferiority_desc>
            <p_value>0.0074</p_value>
            <p_value_desc>The null hypothesis is that the difference between treatment groups (1.5g TRC101 BID - Pooled Placebo) in proportion of subjects whose serum bicarbonate increased from baseline to Day 15 by =&gt; 4 mEq/L = 0.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Two-group test</non_inferiority_desc>
            <p_value>0.0012</p_value>
            <p_value_desc>The null hypothesis is that the difference between treatment groups (3g TRC101 BID - Pooled Placebo) in proportion of subjects whose serum bicarbonate increased from baseline to Day 15 by =&gt; 2 mEq/L = 0.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Two-group test</non_inferiority_desc>
            <p_value>0.0032</p_value>
            <p_value_desc>The null hypothesis is that the difference between treatment groups (3g TRC101 BID - Pooled Placebo) in proportion of subjects whose serum bicarbonate increased from baseline to Day 15 by =&gt; 3 mEq/L = 0.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Two-group test</non_inferiority_desc>
            <p_value>0.0013</p_value>
            <p_value_desc>The null hypothesis is that the difference between treatment groups (3g TRC101 BID - Pooled Placebo) in proportion of subjects whose serum bicarbonate increased from baseline to Day 15 by =&gt; 4 mEq/L = 0.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Two-group test</non_inferiority_desc>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>The null hypothesis is that the difference between treatment groups (4.5g TRC101 BID - Pooled Placebo) in proportion of subjects whose serum bicarbonate increased from baseline to Day 15 by =&gt; 2 mEq/L = 0.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Two-group test</non_inferiority_desc>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>The null hypothesis is that the difference between treatment groups (4.5g TRC101 BID - Pooled Placebo) in proportion of subjects whose serum bicarbonate increased from baseline to Day 15 by =&gt; 3 mEq/L = 0.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Two-group test</non_inferiority_desc>
            <p_value>&lt; 0.0006</p_value>
            <p_value_desc>The null hypothesis is that the difference between treatment groups (4.5g TRC101 BID - Pooled Placebo) in proportion of subjects whose serum bicarbonate increased from baseline to Day 15 by =&gt; 4 mEq/L = 0.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Serum Bicarbonate at Day 15 Within the TRC101 6g QD Dose Group</title>
        <description>Serum bicarbonate at Day 15 minus serum bicarbonate at Baseline</description>
        <time_frame>Baseline and Day 15</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>6g TRC101 QD</title>
            <description>6g TRC101 administered once daily (QD) for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Serum Bicarbonate at Day 15 Within the TRC101 6g QD Dose Group</title>
          <description>Serum bicarbonate at Day 15 minus serum bicarbonate at Baseline</description>
          <population>Full Analysis Set</population>
          <units>mEq/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Single-group test</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The null hypothesis is that the mean change from baseline within the 6g TRC101 QD group = 0 mEq/L.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Group LS mean</param_type>
            <param_value>3.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.7</ci_lower_limit>
            <ci_upper_limit>4.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Serum Bicarbonate at Day 15 Comparison Between the TRC101 6g QD Dose Group Versus Placebo</title>
        <description>Serum bicarbonate at Day 15 minus serum bicarbonate at Baseline for the TRC101 6g dose group versus that for Placebo</description>
        <time_frame>Baseline and Day 15</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo</title>
            <description>Pooled placebo treatment groups (Placebo administered twice daily [BID] for 14 days + Placebo administered once daily [QD] for 14 days)</description>
          </group>
          <group group_id="O2">
            <title>6g TRC101 QD</title>
            <description>6g TRC101 administered once daily (QD) for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Serum Bicarbonate at Day 15 Comparison Between the TRC101 6g QD Dose Group Versus Placebo</title>
          <description>Serum bicarbonate at Day 15 minus serum bicarbonate at Baseline for the TRC101 6g dose group versus that for Placebo</description>
          <population>Full Analysis Set</population>
          <units>mEq/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="0.4"/>
                    <measurement group_id="O2" value="3.5" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Two-group test</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The null hypothesis is the difference between treatment groups (6g TRC101 QD - Pooled Placebo) in the mean change from baseline = 0 mEq/L.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Difference between group LS means</param_type>
            <param_value>3.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.5</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.6</ci_lower_limit>
            <ci_upper_limit>4.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Serum Bicarbonate at Day 15 Comparison Between the TRC101 6g QD Dose Group Versus the TRC101 3g BID Dose Group</title>
        <description>Serum bicarbonate at Day 15 minus serum bicarbonate at Baseline for the TRC101 6g QD dose group versus that for the TRC101 3g BID dose group</description>
        <time_frame>Baseline and Day 15</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>3g TRC101 BID</title>
            <description>3g TRC101 administered twice daily (BID) for 14 days</description>
          </group>
          <group group_id="O2">
            <title>6g TRC101 QD</title>
            <description>6g TRC101 administered once daily (QD) for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Serum Bicarbonate at Day 15 Comparison Between the TRC101 6g QD Dose Group Versus the TRC101 3g BID Dose Group</title>
          <description>Serum bicarbonate at Day 15 minus serum bicarbonate at Baseline for the TRC101 6g QD dose group versus that for the TRC101 3g BID dose group</description>
          <population>Full Analysis Set</population>
          <units>mEq/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="0.4"/>
                    <measurement group_id="O2" value="3.5" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Two-group test</non_inferiority_desc>
            <p_value>0.4214</p_value>
            <p_value_desc>The null hypothesis is that the difference between treatment groups (3g TRC101 BID - 6g TRC101 QD) in the mean change from baseline = 0 mEq/L.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Difference between group LS means</param_type>
            <param_value>-0.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.6</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.6</ci_lower_limit>
            <ci_upper_limit>0.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of the Proportion of Subjects in the TRC101 6g QD Dose Group Whose Serum Bicarbonate Values Increased From Baseline to Day 15 by Greater Than or Equal to 2, 3, or 4 mEq/L Versus Placebo</title>
        <description>Comparison of the proportion of subjects whose serum bicarbonate values increased from Baseline to Day 15 by greater than or equal to 2, 3, or 4 mEq/L between the 6g TRC101 QD Dose Group versus Placebo</description>
        <time_frame>Baseline and Day 15</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo</title>
            <description>Pooled placebo treatment groups (Placebo administered twice daily [BID] for 14 days + Placebo administered once daily [QD] for 14 days)</description>
          </group>
          <group group_id="O2">
            <title>6g TRC101 QD</title>
            <description>6g TRC101 administered once daily (QD) for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of the Proportion of Subjects in the TRC101 6g QD Dose Group Whose Serum Bicarbonate Values Increased From Baseline to Day 15 by Greater Than or Equal to 2, 3, or 4 mEq/L Versus Placebo</title>
          <description>Comparison of the proportion of subjects whose serum bicarbonate values increased from Baseline to Day 15 by greater than or equal to 2, 3, or 4 mEq/L between the 6g TRC101 QD Dose Group versus Placebo</description>
          <population>Full Analysis Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>=&gt; 2 mEq/L Baseline Serum Bicarbonate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>=&gt; 3 mEq/L Baseline Serum Bicarbonate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>=&gt; 4 mEq/L Baseline Serum Bicarbonate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Two-group test</non_inferiority_desc>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>The null hypothesis is that the difference between treatment groups (6g TRC101 QD - Pooled Placebo) in proportion of subjects whose serum bicarbonate increased from baseline to Day 15 by =&gt; 2 mEq/L = 0.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Two-group test</non_inferiority_desc>
            <p_value>0.0003</p_value>
            <p_value_desc>The null hypothesis is that the difference between treatment groups (6g TRC101 QD - Pooled Placebo) in the proportion of subjects whose serum bicarbonate increased from baseline to Day 15 by =&gt; 3 mEq/L = 0.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Two-group test</non_inferiority_desc>
            <p_value>0.0003</p_value>
            <p_value_desc>The null hypothesis is that the difference between treatment groups (6g TRC101 QD - Pooled Placebo) in the proportion of subjects whose serum bicarbonate increased from baseline to Day 15 by =&gt; 4 mEq/L = 0.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Through treatment period completion (Day 15)</time_frame>
      <desc>All subjects completed dosing per protocol and are included in the safety results.</desc>
      <group_list>
        <group group_id="E1">
          <title>Pooled Placebo</title>
          <description>Pooled Placebo treatment group (Placebo administered twice daily [BID] for 14 days + Placebo administered once daily [QD] for 14 days)</description>
        </group>
        <group group_id="E2">
          <title>1.5g TRC101 BID</title>
          <description>1.5g TRC101 administered twice daily (BID) for 14 days</description>
        </group>
        <group group_id="E3">
          <title>3g TRC101 BID</title>
          <description>3g TRC101 administered twice daily (BID) for 14 days</description>
        </group>
        <group group_id="E4">
          <title>4.5g TRC101 BID</title>
          <description>4.5g TRC101 administered twice daily (BID) for 14 days</description>
        </group>
        <group group_id="E5">
          <title>6g TRC101 QD</title>
          <description>6g TRC101 administered once daily (QD) for 14 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Glomerular filtration rate decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Information</name_or_title>
      <organization>Tricida, Inc.</organization>
      <phone>415-429-7800</phone>
      <email>medinfo@tricida.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

